BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/31/2025 5:47:44 AM | Browse: 2 | Download: 11
 |
Received |
|
2025-08-27 23:06 |
|
Peer-Review Started |
|
2025-08-27 23:06 |
|
First Decision by Editorial Office Director |
|
2025-09-04 06:56 |
|
Return for Revision |
|
2025-09-04 06:56 |
|
Revised |
|
2025-09-13 13:55 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-11-06 02:48 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-06 06:31 |
|
Articles in Press |
|
2025-11-06 06:31 |
|
Edit the Manuscript by Language Editor |
|
2025-11-09 02:29 |
|
Typeset the Manuscript |
|
2025-12-19 02:42 |
|
Publish the Manuscript Online |
|
2025-12-31 05:47 |
| ISSN |
2220-3206 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Psychiatry |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Initial lurasidone dosing in acute schizophrenia: Pragmatic and trajectory-aware clinical implications
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yang Liu and Tao Liu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Tao Liu, Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Xicheng District, Beijing 100053, China. liu_t2019@163.com |
| Key Words |
Lurasidone; Schizophrenia; Antipsychotic agents; Treatment outcome; Akathisia; Body weight |
| Core Tip |
Choosing a starting dose may influence the early clinical trajectory in acute schizophrenia. In a pragmatic randomized study, 80 mg/day for the first week led to more rapid improvement in Positive and Negative Syndrome Scale positive symptoms than 40 mg/day, with similar discontinuation for adverse events and no short-term metabolic penalty. Clinicians may prioritize speed with 80 mg/day when tolerated, or start at 40 mg/day when akathisia risk is a concern, coupled with a day-7 review for escalation. Open-label design and dose convergence temper causal claims, but initial dose selection may shape the early trajectory. |
| Publish Date |
2025-12-31 05:47 |
| Citation |
Liu Y, Liu T. Initial lurasidone dosing in acute schizophrenia: Pragmatic and trajectory-aware clinical implications. World J Psychiatry 2026; 16(1): 113548 |
| URL |
https://www.wjgnet.com/2220-3206/full/v16/i1/113548.htm |
| DOI |
https://dx.doi.org/10.5498/wjp.v16.i1.113548 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
